Compare Aurora Cannabis Inc (ACB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Aurora Cannabis Inc vs Merck & Co., Inc. — how do they compare? Aurora Cannabis Inc trades at $2.68 (market cap $165.36M), while Merck & Co., Inc. trades at $126.01 (market cap $318.26B). The key difference: Merck & Co., Inc. is far larger — about 1924.6× Aurora Cannabis Inc's market cap, and Merck & Co., Inc. pays a 2.64% dividend while Aurora Cannabis Inc pays none. Which is the better fit depends on your goals.
| ACB | MRK | |
|---|---|---|
Market Cap | $165.36M | $318.26B |
Sector | Health | Health |
52-Week High | $6.23 | $129.52 |
52-Week Low | $2.67 | $77.60 |
Enterprise Value | $99.82M | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aurora Cannabis (ACB) trades at $2.71, down 4.58% on the day, with a bearish technical outlook. The company reported a net income of $1.59 million in 2025, a significant improvement from a $69 million loss in 2024, though 2026 guidance projects a net loss of $136 million. Revenue grew to $343.29 million in 2025, but faces headwinds from Canadian reimbursement pressures. Analyst consensus is mixed, with 21.43% buy, 57.14% hold, and 21.43% sell ratings.
The stock's low P/B of 0.47 suggests undervaluation, but negative profitability metrics and a projected reset year in 2027 pose risks. Investment appeal hinges on execution in high-margin international medical markets, though volatility and competitive pressures remain key concerns for shareholders.
Merck (MRK) trades at $126.00, down 0.62% today, with a bullish technical outlook supported by moving averages and strong institutional buying. The company reported solid earnings beats in recent quarters, with Q1 2026 loss narrower than expected. Revenue reached $65.01B in 2025, with net income margin improving to 28.07%. Recent acquisition of Terns Pharmaceuticals for approximately $6.7 billion aims to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook remains positive with a consensus price target of $139.33, implying 11% upside, supported by 67.6% analyst buy ratings. Risks include rising debt-to-asset ratio to 36.06% in 2025 and projected net cash flow decline to -$3.3B in 2026. Competitive pressures in pharma and macroeconomic uncertainties could challenge growth, but strong profitability and dividend yield offer defensive appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aurora Cannabis Inc
Aurora Cannabis, based in Edmonton, Canada, grows and distributes both medical and recreational cannabis under several brands, including Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. While its main market is Canada, the company has also expanded globally through medical cannabis export agreements.
Read more on ACB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
